This federal contract Indefinite Delivery Vehicle (IDV) is a $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) awarded by the U.S. Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The prime contractor is a prominent pharmaceutical manufacturer specializing in biologic therapies for cancer, immunology, and infectious diseases. The contract does not have any set-aside designations, as Janssen Biotech is a large, for-profit organization.
Under this IDV, the VA and its Veterans Integrated Service Networks (VISNs) are able to efficiently procure critical oncology and specialty medications to support comprehensive healthcare services for veteran patients nationwide. The contract vehicle includes firm fixed price delivery orders for products such as BALVERSA (erdafitinib), CARVYKTI (ciltacabtagene autoleucel), and WELIREG (belzutifan). Additionally, Janssen Biotech holds Blanket Purchase Agreements (BPAs) valued at $15 million and $3.7 million specifically for BALVERSA, CARVYKTI, and WELIREG, further enabling the VA to streamline procurement of these essential oncology drugs.
Generated 2/6/25, 9:04 AM